RESUMO
Tampa Bay-based BayCare Health System recommends the following actions CFOs can take to guide implementation of an EHR system: Become actively involved in the EHR implementation strategy and project management. Help the organization understand that EHR systems require not just a change in the organization's core clinical system, but also its core revenue system. Monitor revenue by department in the weeks and months after go-live, and move quickly to evaluate unanticipated changes in revenue.
Assuntos
Pessoal Administrativo , Sistemas Computadorizados de Registros Médicos/organização & administração , Papel Profissional , Atenção à Saúde/organização & administração , Administração Financeira , Florida , Estudos de Casos OrganizacionaisRESUMO
Novel series of sphingosine-1-phosphate (S1P) receptor agonists were developed through a systematic SAR aimed to achieve high selectivity for a single member of the S1P family of receptors, S1P1. The optimized structure represents a highly S1P1-selective and efficacious agonist: S1P1/S1P2, S1P1/S1P3, S1P1/S1P4>10,000-fold, S1P1/S1P5>600-fold, while EC50 (S1P1) <0.2 nM. In vivo experiments are consistent with S1P1 receptor agonism alone being sufficient for achieving desired lymphocyte-lowering effect.
Assuntos
Imunossupressores/síntese química , Imunossupressores/farmacologia , Linfócitos/efeitos dos fármacos , Receptores de Lisoesfingolipídeo/agonistas , Animais , Células CHO , Cricetinae , Contagem de Linfócitos , Linfócitos/citologia , Relação Estrutura-AtividadeRESUMO
3-(N-Alkyl)aminopropylphosphonic acids are potent agonists of four of the five known sphingosine-1-phosphate (S1P) receptor subtypes.
Assuntos
Receptores Acoplados a Proteínas G/agonistas , Receptores de Lisoesfingolipídeo/agonistas , Animais , Células CHO , Cricetinae , Humanos , Concentração Inibidora 50 , Ligantes , Organofosfonatos/síntese química , Compostos Organofosforados/síntese química , Radioisótopos de Fósforo , Relação Estrutura-AtividadeRESUMO
Structurally modified 3-(N-benzylamino)propylphosphonic acid S1P receptor agonists that maintain affinity for S1P1, and have decreased affinity for S1P3 are efficacious, but exhibit decreased acute cardiovascular toxicity in rodents than do nonselective agonists.